Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease
2022; Frontiers Media; Volume: 14; Linguagem: Inglês
10.3389/fnagi.2022.887498
ISSN1663-4365
AutoresTandis Parvizi, Theresa König, Raphael Wurm, Sara Silvaieh, Patrick Altmann, Sigrid Klotz, Paulus Rommer, Julia Furtner, Günther Regelsberger, Johann Lehrner, Tatjana Traub‐Weidinger, Ellen Gelpí, Elisabeth Stögmann,
Tópico(s)Advanced Neuroimaging Techniques and Applications
ResumoBlood-based biomarkers may add a great benefit in detecting the earliest neuropathological changes in patients with Alzheimer's disease (AD). We examined the utility of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) regarding clinical diagnosis and differentiation between amyloid positive and negative patients. To evaluate the practical application of these biomarkers in a routine clinical setting, we conducted this study in a heterogeneous memory-clinic population.
Referência(s)